Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer

BJU International

Volumn 104, Issue 1, 2009, Pages 29-34

  Thomas, Christian ^a   Wiesner, Christoph ^a   Melchior, Sebastian W ^a   Schmidt, Folke ^a   Gillitzer, Rolf ^a   Thüroff, Joachim W ^a   Pfitzenmaier, Jesco ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cytokeratin; Disseminated tumour cells; Prostate cancer; Urokinase plasminogen activator receptor

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; HORMONE ANALOG; PROSTATE SPECIFIC ANTIGEN; UROKINASE RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD; BLOOD SAMPLING; BONE MARROW; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; TUMOR CELL;

AGED; BONE MARROW; EPIDEMIOLOGIC METHODS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL;

EID: 67650457467     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08298.x     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts and Figures 2008. Atlanta : American Cancer Society, 2008 : 5 6
2. Roberts W, Bergstralh E, Besse J, Blute M. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001 57 : 1033 7
3. Pfitzenmaier J, Vessella RL, Ellis WJ, Lange PH. Detection, isolation, and study of disseminated prostate cancer cells in the peripheral blood and bone marrow. In Pantel K, Micrometastases, Chapt. 5. Berlin : Kluwer, 2002
4. Hofmann T, Riesenberg R, Buchner A, Zimmermann W, Hofstetter A, Oberneder R. Disseminated tumor cells in bone marrow of patients with transitional cell carcinoma: immunocytochemical detection and correlation with established prognostic indicators. J Urol 2003 169 : 1303 7
5. Ellis W, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vesella RL. Detection and isolation of prostate cancer cells form peripheral blood and bone marrow. Urology 2003 61 : 277 81
6. Helenius MA, Saramaki OR, Linja MJ. Amplification of urokinase gene in prostate cancer. Cancer Res 2001 61 : 5340 4
7. Dano K. The urokinase receptor. Protein structure and role in plasminogen activation an cancer invasion. Fibrinolysis 1994 8 : 198 203
8. Dano K. Cancer invasion and tissue remodelling-cooperation of protease systems and cell types. APMIS 1999 107 : 120 7
9. Festuccia C, Dolo V, Guerra F et al. Plasminogen activation system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 1998 15 : 513 28
10. Gaylis F. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 1989 142 : 193 8
11. Allgayer H, Heiss M, Riesenberg R et al. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 1997 57 : 1394 9
12. Hemsen AA. Profiling of the urokinase-type activation system in breast cancer: correlation to occult bone marrow micrometastasis. Proc AACR 2002 43 : 732
13. Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R. Comparison oft wo density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 2002 49 : 150 8
14. R Instruction Manual. Rev. 6/2004
15. Allgayer H, Heiss MM, Riesenberg R et al. Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA-R and CK 18: investigation of sensitivity, specicity and reproducibility of an immunogold/alkaline phosphatase double-staining protocol. J Histochem Cytochem 1997 45 : 203 12
16. DAKO. DAKO Kit: EnVision Double Stain System Instructions. Code no. K1395
17. D'Amico AV, Whittington R, Malkowicz B et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 1998 280 : 969 74
18. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998 16 : 557
19. Bretton P, Melamed M, Fair W, Cote R. Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Prostate 1994 25 : 108 14
20. Weckermann D, Muller P, Wawroschek F, Krawczak G, Riethmuller G, Schlimok G. Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol 1999 17 : 3438 43
21. Pantel K, Aignherr C, Kollermann J, Caprano J, Riethmuller G, Kollerman M. Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. Eur J Cancer 1995 31 : 1627 32
22. Oberneder R, Riesenberg R, Kriegmair M et al. Immunocytochemical detection and phenotypic characterization of micrometastatic tumor cells in bone marrow of patients with prostate cancer. Urol Res 1994 22 : 3 8 (Pubitemid 24149213)
23. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kenternich C. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med 2000 342 : 525 33
24. Pierga J, Bonneton C, Magdelenat H, Vincent-Salomon A, Nos C, Boudou E. Real-time quantiative PCR determination of urokinase-type plasminogen activator receptor (uPA-R) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 2005 114 : 291 8
25. Berger D. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002 26 : 767 71
26. Li Y, Cozzi PJ. Targeting uPA/uPA-R in prostate cancer. Cancer Treat Rev 2007 33 : 521 7
27. Shariat SF, Roehrborn C, McConnell J et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007 25 : 349 55
28. Heiss M, Allgayer H, Gruetzner K et al. Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995 1 : 1035 9
29. Morrissey C, Vessella R. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 2007 101 : 873 86
30. Morgan T, Lange P, Vessella R. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 2007 12 : 3000 9
31. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase activator receptor, uPA-R. Stem Cells 1997 15 : 398 408 (Pubitemid 27513714)
32. Braun S, Vogl F, Schneitter A et al. Disseminated tumor cells: are they ready for clinical use? Breast 2007 16 : 51 4